San Diego-based Vical Inc. signed a potential $130 million-plus license agreement with Astellas Pharma Inc., of Tokyo, for worldwide development and commercialization of Vical's TransVax vaccine for cytomegalovirus (CMV) reactivation in hematopoietic stem cell transplant and solid organ transplant recipients.